NSPR
InspireMD, Inc. NASDAQ Listed Apr 12, 2011$0.68
-2.93%
vs $0.70
Mkt Cap $31.8M
52w Low $0.66
0.8% of range
52w High $2.93
50d MA $1.03
200d MA $1.71
P/E (TTM)
—
EV/EBITDA
—
P/B
0.9x
Debt/Equity
0.0x
ROE
-88.4%
P/FCF
-1.4x
RSI (14)
17.90
ATR (14)
$0.09
Beta
0.94
50d MA
$1.03
200d MA
$1.71
Avg Volume
175.5K
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery. It is also developing PVGuard, a MicroNet mesh sleeve and self-expandable stent for use in peripheral vascular applications. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.
4 Menorat Hamaor Street · Miami, FL 6744832 · IL
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 4, 2026 | AMC | -0.19 | -0.16 | +15.8% | 1.17 | -12.8% | -6.0% | +5.5% | +0.0% | -0.9% | +8.7% | — |
| Mar 18, 2026 | AMC | -0.22 | -0.14 | +36.4% | 1.79 | +0.0% | -4.5% | +5.8% | -3.9% | +2.9% | -1.1% | — |
| Nov 4, 2025 | AMC | -0.17 | -0.17 | +0.0% | 2.13 | +0.0% | -0.9% | -7.1% | -7.7% | -7.2% | -3.0% | — |
| Aug 4, 2025 | AMC | -0.24 | -0.26 | -8.3% | 2.67 | +1.1% | -8.2% | +2.0% | -4.4% | +1.3% | +6.6% | — |
| May 9, 2025 | AMC | -0.17 | -0.22 | -29.4% | 2.60 | +1.9% | -0.8% | -5.8% | -2.9% | +0.4% | -0.4% | — |
| Mar 12, 2025 | AMC | -0.20 | -0.19 | +5.0% | 2.81 | +1.4% | +2.1% | -2.4% | +0.0% | +0.0% | +0.0% | — |
| Nov 12, 2024 | AMC | -0.20 | -0.16 | +20.0% | 2.38 | -10.9% | +5.5% | +1.6% | -0.8% | +2.4% | -0.8% | — |
| Aug 6, 2024 | AMC | -0.19 | -0.22 | -15.8% | 2.98 | -1.7% | -4.0% | -0.3% | +0.4% | -0.7% | +3.9% | — |
| May 14, 2024 | AMC | -0.15 | -0.21 | -40.0% | 2.38 | -0.8% | -3.4% | +0.0% | +0.0% | -0.9% | +2.2% | — |
| Mar 6, 2024 | AMC | -0.20 | -0.16 | +20.0% | 2.53 | -2.8% | +4.3% | -0.4% | -3.0% | -3.5% | +1.6% | — |
| Nov 6, 2023 | AMC | -0.17 | -0.15 | +11.8% | 3.34 | -3.0% | -3.0% | +0.0% | -4.6% | +1.6% | -2.5% | — |
| Aug 8, 2023 | AMC | -0.17 | -0.24 | -41.2% | 3.10 | +4.5% | +0.0% | +3.5% | +0.0% | -2.2% | +0.6% | — |
| May 15, 2023 | AMC | -0.68 | -0.53 | +22.1% | 1.84 | -8.7% | -8.7% | +4.8% | -3.4% | +5.9% | +5.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 12 | Piper Sandler | Maintains | Overweight → Overweight | — | $2.60 | $2.65 | +1.9% | -0.8% | -5.8% | -2.9% | +0.4% | -0.4% |
| Nov 2 | Piper Sandler | Maintains | Overweight → Overweight | — | $3.77 | $3.29 | -12.7% | -11.4% | +3.1% | -3.0% | -3.0% | +0.0% |
| Jun 12 | Piper Sandler | Maintains | Overweight → Overweight | — | $1.69 | $1.90 | +12.4% | +7.7% | +1.6% | +7.6% | +3.0% | +16.1% |
| May 17 | National Alliance Securities | Maintains | Buy → Buy | — | $1.68 | $1.76 | +4.8% | +4.8% | -3.4% | +5.9% | +5.6% | -6.8% |
| Mar 31 | Alliance Global Partners | Maintains | Buy → Buy | — | $1.06 | $1.07 | +0.9% | +6.6% | -4.4% | +0.0% | +5.6% | -4.4% |
| Mar 11 | H.C. Wainwright | Maintains | Buy → Buy | — | $9.90 | $9.15 | -7.6% | -3.0% | -14.1% | -3.6% | -5.7% | +0.0% |
| Mar 29 | Rodman & Renshaw | Maintains | Buy → Buy | — | $248437.50 | $257812.50 | +3.8% | -3.8% | +2.0% | -1.9% | -2.0% | -4.0% |
| Jan 7 | H.C. Wainwright | Maintains | Buy → Buy | — | $332812.50 | $370312.50 | +11.3% | +0.0% | +15.5% | -2.4% | -12.5% | +0.0% |
| Mar 13 | Oppenheimer | Downgrade | Outperform → Perform | — | — | — | — | — | — | — | — | — |
| Nov 26 | Oppenheimer | Maintains | Outperform → Outperform | — | — | — | — | — | — | — | — | — |
| May 8 | TD Cowen | Maintains | Outperform → Outperform | — | — | — | — | — | — | — | — | — |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 27, 2026 | Stuka PaulDir | — | Buy | 20,000 | $0.88 | $18K | 667,871 | +7.53% | -4.86% |
| May 14, 2026 | Stuka PaulDir | — | Buy | 5,000 | $1.15 | $6K | 647,871 | +0.00% | -2.91% |
| May 13, 2026 | Stuka PaulDir | — | Buy | 10,000 | $1.16 | $12K | 642,871 | +0.00% | -2.91% |
| May 12, 2026 | Slosman MarvinDir/Off | CEO and President | Buy | 21,000 | $1.20 | $25K | 3,556,658 | -2.56% | +0.00% |
| May 11, 2026 | Stuka PaulDir | — | Buy | 10,000 | $1.19 | $12K | 632,871 | -2.56% | +0.00% |
| May 11, 2026 | Stuka PaulDir | — | Buy | 10,000 | $1.19 | $12K | 632,871 | -2.50% | -4.76% |
| May 8, 2026 | Stuka PaulDir | — | Buy | 65,626 | $1.16 | $76K | 622,871 | -2.56% | +0.00% |
| May 8, 2026 | Stuka PaulDir | — | Buy | 65,626 | $1.16 | $76K | 622,871 | -2.50% | -4.76% |
8-K · 7.01
! Medium
InspireMD, Inc. -- 8-K 7.01: Regulation FD Disclosure
Jun 11
8-K · 5.03
! Medium
InspireMD, Inc. -- 8-K 5.03: Amendment to Articles / Bylaws
Jun 3
8-K · 8.01
!! High
InspireMD, Inc. -- 8-K 8.01: Material Event / Announcement
InspireMD filed an 8-K to disclose material press releases, though the specific announcement details aren't fully summarized in the filing excerpt provided.
May 1
8-K · 1.01
!! High
Unknown — 8-K 1.01: Distribution Agreement
NSPR signed a distribution agreement with BTIG, likely expanding market access and trading liquidity for the stock, which could reduce spreads and attract institutional investors.
Apr 3
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
NSPR disclosed material non-public information via Regulation FD, suggesting the company made an unexpected announcement that could significantly impact stock valuation and trading, requiring immediate investor attention.
Mar 18
8-K · 5.02
!!! Very High
InspireMD, Inc. -- 8-K 5.02: Executive Change
InspireMD's executive Tommasoli remains employed under a French contract with six-month dismissal notice requirements, potentially limiting the company's flexibility in personnel changes.
Mar 4
Valuation
Market Cap
$31.8M
Enterprise Value
-$2.8M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.00x
P/B
0.90x
P/S
4.60x
P/FCF
-1.40x
EV/EBITDA
—
Shares Out
73.5M
Financials (TTM)
Revenue
$10.8M
Net Income
-$37.3M
EBITDA
-$36.6M
Free Cash Flow
-$36.8M
Op Cash Flow
-$35.1M
EPS Basic
$-0.76
EPS Diluted
$-0.57
EPS Forward
$-0.73
Gross Margin
28.1%
Op Margin
-480.6%
Net Margin
-344.1%
Balance Sheet
Total Assets
$69.4M
Total Liab.
$14.2M
Total Equity
$55.2M
Cash
$54.2M
LT Debt
$0
Book Value/Sh
$0.75
Debt/Equity
0.04x
Current Ratio
5.74
Quick Ratio
5.42
Returns & Growth
ROE
-88.4%
ROA
-70.3%
ROIC
-83.7%
Rev Growth YoY
+28.1%
EPS Growth YoY
—
Price Returns
2W
-19.2%
1M
-22.0%
3M
-48.3%
6M
-53.5%
12M
-64.0%
Technicals
52W High
$2.93
52W Low
$0.66
50d MA
$1.03
200d MA
$1.71
RSI (14)
17.90
ATR (14)
$0.09
Beta
0.94
Avg Volume
176K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$5.50
High
$6.00
Low
$5.00
Median
$5.50
Data updated apr 26, 2026 3:51pm
· Source: financialmodelingprep.com